Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials
Bettina Diekamp,1 Stephane Borentain,2 Dong-Jing Fu,3 Robert Murray,4 Kristin Heerlein,1 Qiaoyi Zhang,5 Cornelius Schüle,6 Maju Mathews2 1Department of Medical and Scientific Affairs, Janssen-Cilag GmbH, Neuss, Germany; 2Department of Global Medical Affairs, Janssen Research & Development LLC, T...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-07-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Subjects: | |
| Online Access: | https://www.dovepress.com/effect-of-concomitant-benzodiazepine-use-on-efficacy-and-safety-of-esk-peer-reviewed-fulltext-article-NDT |
| _version_ | 1818433960914452480 |
|---|---|
| author | Diekamp B Borentain S Fu DJ Murray R Heerlein K Zhang Q Schüle C Mathews M |
| author_facet | Diekamp B Borentain S Fu DJ Murray R Heerlein K Zhang Q Schüle C Mathews M |
| author_sort | Diekamp B |
| collection | DOAJ |
| description | Bettina Diekamp,1 Stephane Borentain,2 Dong-Jing Fu,3 Robert Murray,4 Kristin Heerlein,1 Qiaoyi Zhang,5 Cornelius Schüle,6 Maju Mathews2 1Department of Medical and Scientific Affairs, Janssen-Cilag GmbH, Neuss, Germany; 2Department of Global Medical Affairs, Janssen Research & Development LLC, Titusville, NJ, USA; 3Department of Neuroscience Clinical Development, Janssen Research & Development LLC, Titusville, NJ, USA; 4Neuroscience Clinical Biostatistics, Janssen Research & Development LLC, Titusville, NJ, USA; 5Global Market Access, Neuroscience, Janssen Global Services, LLC, Titusville, NJ, USA; 6Ludwig-Maximilians-University Munich, Clinic for Psychiatry and Psychotherapy, Munich, GermanyCorrespondence: Bettina DiekampDepartment of Medical and Scientific Affairs, Janssen-Cilag GmbH, Johnson & Johnson Platz 1, Neuss, 41470, GermanyTel +49-21379556179Email bdiekamp@its.jnj.comPurpose: The impact of benzodiazepines on the efficacy and safety of esketamine as a rapid-acting antidepressant remains unclear.Materials and Methods: Data from two identically designed, randomized double-blind studies were pooled and analyzed on a post-hoc basis. In both studies, adults with major depressive disorder with acute suicidal ideation or behavior were randomized to placebo or esketamine 84 mg nasal spray twice-weekly for 4 weeks, each with comprehensive standard-of-care (initial hospitalization and newly initiated or optimized oral antidepressant[s]). Efficacy and safety were analyzed in two groups based on whether patients used concomitant benzodiazepines, which were prohibited within 8 hours before and 4 hours after the first dose of esketamine and within 8 hours of the primary efficacy assessment at 24 hours. The primary efficacy endpoint – change from baseline to 24 hours post-first dose in Montgomery-Asberg Depression Rating Scale (MADRS) total score – was analyzed using ANCOVA.Results: Most patients (309/451, 68.5%) used concomitant benzodiazepines. Greater decrease in MADRS total score was observed with esketamine (mean [SD]: − 16.1 [11.73]) versus placebo (− 12.6 [10.56]) at 24 hours (least-squares mean difference: − 3.7, 95% CI: − 5.76, − 1.59). The differences between the esketamine and placebo groups were clinically meaningful, irrespective of benzodiazepine use (benzodiazepine: − 4.3 [− 6.63, − 1.89]; no benzodiazepine: − 3.1 [− 6.62, 0.45]). Among patients taking esketamine, change in MADRS total score was not significantly different between patients taking benzodiazepines (− 15.8 [11.27]) versus those not taking benzodiazepines (− 16.8 [12.82]) (least-squares mean difference: 1.1, [− 2.24, 4.45]). Among esketamine-treated patients, the incidence of sedation was higher with benzodiazepine use, whereas dissociation was similar.Conclusion: Benzodiazepines do not meaningfully affect the rapid-acting antidepressant effect of esketamine at 24 hours post-first dose among patients with MDD and acute suicidal ideation or behavior.Keywords: esketamine, benzodiazepine, depression, suicidal ideation, rapid-acting |
| first_indexed | 2024-12-14T16:29:24Z |
| format | Article |
| id | doaj.art-a411f610d609435393ad87721156590b |
| institution | Directory Open Access Journal |
| issn | 1178-2021 |
| language | English |
| last_indexed | 2024-12-14T16:29:24Z |
| publishDate | 2021-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Neuropsychiatric Disease and Treatment |
| spelling | doaj.art-a411f610d609435393ad87721156590b2022-12-21T22:54:37ZengDove Medical PressNeuropsychiatric Disease and Treatment1178-20212021-07-01Volume 172347235766986Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled TrialsDiekamp BBorentain SFu DJMurray RHeerlein KZhang QSchüle CMathews MBettina Diekamp,1 Stephane Borentain,2 Dong-Jing Fu,3 Robert Murray,4 Kristin Heerlein,1 Qiaoyi Zhang,5 Cornelius Schüle,6 Maju Mathews2 1Department of Medical and Scientific Affairs, Janssen-Cilag GmbH, Neuss, Germany; 2Department of Global Medical Affairs, Janssen Research & Development LLC, Titusville, NJ, USA; 3Department of Neuroscience Clinical Development, Janssen Research & Development LLC, Titusville, NJ, USA; 4Neuroscience Clinical Biostatistics, Janssen Research & Development LLC, Titusville, NJ, USA; 5Global Market Access, Neuroscience, Janssen Global Services, LLC, Titusville, NJ, USA; 6Ludwig-Maximilians-University Munich, Clinic for Psychiatry and Psychotherapy, Munich, GermanyCorrespondence: Bettina DiekampDepartment of Medical and Scientific Affairs, Janssen-Cilag GmbH, Johnson & Johnson Platz 1, Neuss, 41470, GermanyTel +49-21379556179Email bdiekamp@its.jnj.comPurpose: The impact of benzodiazepines on the efficacy and safety of esketamine as a rapid-acting antidepressant remains unclear.Materials and Methods: Data from two identically designed, randomized double-blind studies were pooled and analyzed on a post-hoc basis. In both studies, adults with major depressive disorder with acute suicidal ideation or behavior were randomized to placebo or esketamine 84 mg nasal spray twice-weekly for 4 weeks, each with comprehensive standard-of-care (initial hospitalization and newly initiated or optimized oral antidepressant[s]). Efficacy and safety were analyzed in two groups based on whether patients used concomitant benzodiazepines, which were prohibited within 8 hours before and 4 hours after the first dose of esketamine and within 8 hours of the primary efficacy assessment at 24 hours. The primary efficacy endpoint – change from baseline to 24 hours post-first dose in Montgomery-Asberg Depression Rating Scale (MADRS) total score – was analyzed using ANCOVA.Results: Most patients (309/451, 68.5%) used concomitant benzodiazepines. Greater decrease in MADRS total score was observed with esketamine (mean [SD]: − 16.1 [11.73]) versus placebo (− 12.6 [10.56]) at 24 hours (least-squares mean difference: − 3.7, 95% CI: − 5.76, − 1.59). The differences between the esketamine and placebo groups were clinically meaningful, irrespective of benzodiazepine use (benzodiazepine: − 4.3 [− 6.63, − 1.89]; no benzodiazepine: − 3.1 [− 6.62, 0.45]). Among patients taking esketamine, change in MADRS total score was not significantly different between patients taking benzodiazepines (− 15.8 [11.27]) versus those not taking benzodiazepines (− 16.8 [12.82]) (least-squares mean difference: 1.1, [− 2.24, 4.45]). Among esketamine-treated patients, the incidence of sedation was higher with benzodiazepine use, whereas dissociation was similar.Conclusion: Benzodiazepines do not meaningfully affect the rapid-acting antidepressant effect of esketamine at 24 hours post-first dose among patients with MDD and acute suicidal ideation or behavior.Keywords: esketamine, benzodiazepine, depression, suicidal ideation, rapid-actinghttps://www.dovepress.com/effect-of-concomitant-benzodiazepine-use-on-efficacy-and-safety-of-esk-peer-reviewed-fulltext-article-NDTesketaminebenzodiazepinedepressionsuicidal ideationrapid-acting |
| spellingShingle | Diekamp B Borentain S Fu DJ Murray R Heerlein K Zhang Q Schüle C Mathews M Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials Neuropsychiatric Disease and Treatment esketamine benzodiazepine depression suicidal ideation rapid-acting |
| title | Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials |
| title_full | Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials |
| title_fullStr | Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials |
| title_full_unstemmed | Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials |
| title_short | Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials |
| title_sort | effect of concomitant benzodiazepine use on efficacy and safety of esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior pooled randomized controlled trials |
| topic | esketamine benzodiazepine depression suicidal ideation rapid-acting |
| url | https://www.dovepress.com/effect-of-concomitant-benzodiazepine-use-on-efficacy-and-safety-of-esk-peer-reviewed-fulltext-article-NDT |
| work_keys_str_mv | AT diekampb effectofconcomitantbenzodiazepineuseonefficacyandsafetyofesketaminenasalsprayinpatientswithmajordepressivedisorderandacutesuicidalideationorbehaviorpooledrandomizedcontrolledtrials AT borentains effectofconcomitantbenzodiazepineuseonefficacyandsafetyofesketaminenasalsprayinpatientswithmajordepressivedisorderandacutesuicidalideationorbehaviorpooledrandomizedcontrolledtrials AT fudj effectofconcomitantbenzodiazepineuseonefficacyandsafetyofesketaminenasalsprayinpatientswithmajordepressivedisorderandacutesuicidalideationorbehaviorpooledrandomizedcontrolledtrials AT murrayr effectofconcomitantbenzodiazepineuseonefficacyandsafetyofesketaminenasalsprayinpatientswithmajordepressivedisorderandacutesuicidalideationorbehaviorpooledrandomizedcontrolledtrials AT heerleink effectofconcomitantbenzodiazepineuseonefficacyandsafetyofesketaminenasalsprayinpatientswithmajordepressivedisorderandacutesuicidalideationorbehaviorpooledrandomizedcontrolledtrials AT zhangq effectofconcomitantbenzodiazepineuseonefficacyandsafetyofesketaminenasalsprayinpatientswithmajordepressivedisorderandacutesuicidalideationorbehaviorpooledrandomizedcontrolledtrials AT schulec effectofconcomitantbenzodiazepineuseonefficacyandsafetyofesketaminenasalsprayinpatientswithmajordepressivedisorderandacutesuicidalideationorbehaviorpooledrandomizedcontrolledtrials AT mathewsm effectofconcomitantbenzodiazepineuseonefficacyandsafetyofesketaminenasalsprayinpatientswithmajordepressivedisorderandacutesuicidalideationorbehaviorpooledrandomizedcontrolledtrials |